355 related articles for article (PubMed ID: 19956851)
1. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-Delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells.
Shim J; Kim BH; Kim YI; Kim KY; Hwangbo Y; Jang JY; Dong SH; Kim HJ; Chang YW; Chang R
Int J Oncol; 2010 Jan; 36(1):223-31. PubMed ID: 19956851
[TBL] [Abstract][Full Text] [Related]
2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
Lin MS; Chen WC; Bai X; Wang YD
J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.
Zang C; Liu H; Posch MG; Waechter M; Facklam M; Fenner MH; Ruthardt M; Possinger K; Phillip Koeffler H; Elstner E
Leuk Res; 2004 Apr; 28(4):387-97. PubMed ID: 15109539
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines.
Yoshizawa K; Cioca DP; Kawa S; Tanaka E; Kiyosawa K
Cancer; 2002 Nov; 95(10):2243-51. PubMed ID: 12412180
[TBL] [Abstract][Full Text] [Related]
5. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.
Eucker J; Sterz J; Krebbel H; Zavrski I; Kaiser M; Zang C; Heider U; Jakob C; Elstner E; Sezer O
Anticancer Drugs; 2006 Aug; 17(7):763-9. PubMed ID: 16926626
[TBL] [Abstract][Full Text] [Related]
8. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo.
Yu J; Qiao L; Zimmermann L; Ebert MP; Zhang H; Lin W; Röcken C; Malfertheiner P; Farrell GC
Hepatology; 2006 Jan; 43(1):134-43. PubMed ID: 16374840
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Nagata D; Yoshihiro H; Nakanishi M; Naruyama H; Okada S; Ando R; Tozawa K; Kohri K
Cancer Detect Prev; 2008; 32(3):259-66. PubMed ID: 18789607
[TBL] [Abstract][Full Text] [Related]
10. Relationship between peroxisome proliferator-activated receptor-gamma expression and differentiation of human esophageal squamous cell carcinoma.
Takashima T; Fujiwara Y; Hamaguchi M; Sasaki E; Tominaga K; Watanabe T; Oshitani N; Higuchi K; Arakawa T
Oncol Rep; 2005 Apr; 13(4):601-6. PubMed ID: 15756430
[TBL] [Abstract][Full Text] [Related]
11. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats.
Yamamoto Y; Ono T; Dhar DK; Yamanoi A; Tachibana M; Tanaka T; Nagasue N
J Gastroenterol Hepatol; 2008 Jun; 23(6):930-7. PubMed ID: 18565023
[TBL] [Abstract][Full Text] [Related]
12. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma.
Kim KR; Choi HN; Lee HJ; Baek HA; Park HS; Jang KY; Chung MJ; Moon WS
Oncol Rep; 2007 Oct; 18(4):825-32. PubMed ID: 17786342
[TBL] [Abstract][Full Text] [Related]
13. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells.
Emi M; Maeyama K
Biochem Pharmacol; 2004 Apr; 67(7):1259-67. PubMed ID: 15013841
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
15. 15-deoxy-Delta(12,14)-prostaglandin J(2) inhibits fibrogenic response in human hepatoma cells.
Suk FM; Chen CH; Lin SY; Cheng CJ; Yen SJ; Hung LF; Liu DZ; Liang YC
Toxicol Lett; 2009 May; 187(1):22-7. PubMed ID: 19429239
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R
Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma activator 15-deoxy-Delta12,14-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway.
Kim EJ; Park KS; Chung SY; Sheen YY; Moon DC; Song YS; Kim KS; Song S; Yun YP; Lee MK; Oh KW; Yoon DY; Hong JT
J Pharmacol Exp Ther; 2003 Nov; 307(2):505-17. PubMed ID: 12966153
[TBL] [Abstract][Full Text] [Related]
18. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions.
Suzuki T; Hayashi S; Miki Y; Nakamura Y; Moriya T; Sugawara A; Ishida T; Ohuchi N; Sasano H
Endocr Relat Cancer; 2006 Mar; 13(1):233-50. PubMed ID: 16601291
[TBL] [Abstract][Full Text] [Related]
20. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]